Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Canadian-under $3.00 Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: vds4 who wrote (5776)	1/4/2002 9:53:07 PM
From: Al Collard	Respond to of 11802

Hi Martin, Your in with PBP-t @$1.90 for 5,263 shares. Chart for Procyon Biopharma, Inc: stockcharts.com[w,a]dacaniay[dc][pc20!b50!f][vc60][iLa12,26,9!Ll14] From the chart of PBP we can see the stoke broke out this week and is now trading over all it's major MA's. PBP announced a licensing agreement with Biovail today and it's obvious the market liked the news. The volume was outstanding and this stock is definitely in play. Hard to say where the stocks goes from here but it should be volatile and daytradeable. Good luck with this pick, ***** Al

To: vds4 who wrote (5776)	1/7/2002 7:55:58 AM
From: Al Collard	Read Replies (1) \| Respond to of 11802

PBP-t...in the news: NP says Biovail hands Procyon $4-million upfront Mon 7 Jan 2002 Also Biovail Corp (2) (BVF) The National Post reports in its Saturday, Jan. 5, edition that Biovail has acquired United States marketing rights for a patented cream called Fibrostat from Procyon Biopharma. The Post's Robert Gibbens writes that Procyon gets $4-million cash upfront in return for non-convertible preferred shares, a $5-million licensing fee when the product gets U.S. regulatory approval and hits the market by early 2005, plus "double digit" royalties on future sales. The deal includes milestone payments by Biovail. The cash will bring Procyon's liquid resources to about $12-million. With a colorectal cancer diagnostic product due for commercialization in 2003 and Fibrostat later, royalty revenue should start flowing in by 2004 or 2005. Procyon chief executive officer Hans Mader says he is talking to several major drug companies about marketing the product in Europe and Asia. He says: "The North American market potential is $250-million and $600-million worldwide. Patents awarded cover use of the product and active ingredients and it has no direct competitor. It should prove to be high-margin." Biovail bought the Canadian rights for Fibrostat last year for $2.5-million and future royalties.